NCT00076310View on ClinicalTrials.gov

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 28, 2004

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Docetaxel

60 mg/m\^2 IV repeated every 21 days.

DRUG

OSI-774

100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.

DRUG

Cisplatin

75 mg/m\^2 IV every 21 days.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER